Sort   by:  
 Page size 
TranscriptomicsNCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules
This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA...
ORGANISM(S): Homo sapiens 
2015-11-11 | E-GEOD-66999 | biostudies-arrayexpress
TranscriptomicsGene expression changes in CD4+ thymocytes upon removal of Cullin3
We report gene expression changes in Cul3 deficient thymic CD4+ T cells We used microarrays to detail the global programme of gene expression changes upon removal of Cul3 during thymic development CD25-, CD1dPBS57-, gdTCR - CD4+ Single positive cells from thymocytes of CD4Cre-Cul3fl/fl (LM) and CD4 ...
ORGANISM(S): Mus musculus 
2014-04-05 | E-GEOD-56514 | biostudies-arrayexpress
Sort   by:  
 Page size